960495-43-6

960495-43-6 structure

Name: Elubrixin tosylate
Chemical Name: 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea,4-methylbenzenesulfonic acid
CAS Number: 960495-43-6
Molecular Formula: C₂₄H₂₅Cl₂FN₄O₇S₂
Molecular Weight: 635.51200
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2016-06-20 00:34:50
Modify Date: 2024-01-16 17:13:42
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3].

Name	1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea,4-methylbenzenesulfonic acid
Synonyms	UNII-13FVR7WD4P Elubrixin tosylate

Description	Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Signaling Pathways >> GPCR/G Protein >> CXCR Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> CXCR
Target	CXCR2 IL-8
In Vitro	Elubrixin has an inhibitory effect on neutrophils in a dose-dependent fashion[1].
References	[1]. Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24(7):949-56. [2]. Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72(2):282-93. [3]. Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20(1):52-9.

688763-67-9

104-15-4

960495-43-6

Literature: SMITHKLINE BEECHAM CORPORATION Patent: WO2007/150015 A2, 2007 ; Location in patent: Page/Page column 10-11 ; WO 2007/150015 A2